127 related articles for article (PubMed ID: 36463431)
1. The role of serum sphingolipids as potential biomarkers of non-response to direct acting antiviral therapy in chronic hepatitis C virus infection.
Röhrig AM; Jakobi K; Dietz J; Thomas D; Herrmann E; Welsch C; Sarrazin C; Pfeilschifter J; Zeuzem S; Grammatikos G
J Viral Hepat; 2023 Feb; 30(2):138-147. PubMed ID: 36463431
[TBL] [Abstract][Full Text] [Related]
2. Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection.
Grammatikos G; Ferreiros N; Bon D; Schwalm S; Dietz J; Berkowski C; Fitting D; Herrmann E; Zeuzem S; Sarrazin C; Pfeilschifter J
Hepatology; 2015 Mar; 61(3):812-22. PubMed ID: 25348752
[TBL] [Abstract][Full Text] [Related]
3. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response.
Mücke VT; Thomas D; Mücke MM; Waidmann O; Zeuzem S; Sarrazin C; Pfeilschifter J; Vermehren J; Finkelmeier F; Grammatikos G
Liver Int; 2019 Nov; 39(11):2174-2183. PubMed ID: 31207039
[TBL] [Abstract][Full Text] [Related]
4. Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels.
Grammatikos G; Dietz J; Ferreiros N; Koch A; Dultz G; Bon D; Karakasiliotis I; Lutz T; Knecht G; Gute P; Herrmann E; Zeuzem S; Mavromara P; Sarrazin C; Pfeilschifter J
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304952
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal.
Burgui C; San Miguel R; Goñi-Esarte S; Juanbeltz R; Úriz-Otano JI; Reparaz J; Sarobe M; Zozaya JM; Castilla J
Postgrad Med; 2023 May; 135(4):352-360. PubMed ID: 36305320
[TBL] [Abstract][Full Text] [Related]
6. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
[TBL] [Abstract][Full Text] [Related]
8. Reverse inflammaging: Long-term effects of HCV cure on biological age.
Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
[TBL] [Abstract][Full Text] [Related]
9. Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
Virlogeux V; Berthillon P; Bordes I; Larrat S; Crouy S; Scholtès C; Pradat P; Maynard M; Zoulim F; Leroy V; Chemin I; Trépo C; Petit MA
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):313-318. PubMed ID: 29551607
[TBL] [Abstract][Full Text] [Related]
10. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
[TBL] [Abstract][Full Text] [Related]
11. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
[TBL] [Abstract][Full Text] [Related]
12. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
13. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
14. Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.
Montaldo C; Terri M; Riccioni V; Battistelli C; Bordoni V; D'Offizi G; Prado MG; Trionfetti F; Vescovo T; Tartaglia E; Strippoli R; Agrati C; Tripodi M
J Hepatol; 2021 Dec; 75(6):1301-1311. PubMed ID: 34271004
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Ohnami S; Nagashima T; Hatakeyama K; Kakuda Y; Sugino T; Urakami K; Akiyama Y; Yamaguchi K
Cancer Med; 2022 Apr; 11(8):1769-1786. PubMed ID: 35174643
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
20. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
